Cargando…

Practical considerations for the use of mTOR inhibitors

Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Diekmann, Fritz, Campistol, Josep M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895281/
https://www.ncbi.nlm.nih.gov/pubmed/27293552
http://dx.doi.org/10.1186/s13737-015-0029-5
_version_ 1782435817821569024
author Diekmann, Fritz
Campistol, Josep M.
author_facet Diekmann, Fritz
Campistol, Josep M.
author_sort Diekmann, Fritz
collection PubMed
description Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, alternative immunosuppressive strategies are needed that combine excellent efficacy with low incidences of long-term adverse outcomes. This review focuses on the strategies based on mTOR- inhibitors in combination with minimized exposure to CNI.
format Online
Article
Text
id pubmed-4895281
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48952812016-06-10 Practical considerations for the use of mTOR inhibitors Diekmann, Fritz Campistol, Josep M. Transplant Res Review Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, alternative immunosuppressive strategies are needed that combine excellent efficacy with low incidences of long-term adverse outcomes. This review focuses on the strategies based on mTOR- inhibitors in combination with minimized exposure to CNI. BioMed Central 2015-12-22 /pmc/articles/PMC4895281/ /pubmed/27293552 http://dx.doi.org/10.1186/s13737-015-0029-5 Text en © Diekmann and Campistol. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Diekmann, Fritz
Campistol, Josep M.
Practical considerations for the use of mTOR inhibitors
title Practical considerations for the use of mTOR inhibitors
title_full Practical considerations for the use of mTOR inhibitors
title_fullStr Practical considerations for the use of mTOR inhibitors
title_full_unstemmed Practical considerations for the use of mTOR inhibitors
title_short Practical considerations for the use of mTOR inhibitors
title_sort practical considerations for the use of mtor inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895281/
https://www.ncbi.nlm.nih.gov/pubmed/27293552
http://dx.doi.org/10.1186/s13737-015-0029-5
work_keys_str_mv AT diekmannfritz practicalconsiderationsfortheuseofmtorinhibitors
AT campistoljosepm practicalconsiderationsfortheuseofmtorinhibitors